Fate Therapeutics(US:FATE)2023-05-02 16:00Financial Performance - The company has incurred net losses since inception, with significant losses attributed to research and development costs and general administrative expenses [125]. - The company has not generated any revenues from therapeutic product sales or royalties to date, relying instead on collaboration agreements and government grants [128]. - The company anticipates continued operating losses for the foreseeable future as it invests in research and development activities [125]. - As of March 31, 2023, the company had an accumulated deficit of $1.1 billion and anticipates continued net losses for the foreseeable future [154]. - The company expects to incur losses for the foreseeable future as it continues research and development activities, with potential increases in losses anticipated [177]. Collaboration Agreements - Collaboration revenue for the three months ended March 31, 2023, was $52.3 million under the Janssen Agreement, compared to $15.9 million for the same period in 2022 [132]. - The company recognized $6.7 million of collaboration revenue under the Ono Agreement for the three months ended March 31, 2023, up from $2.5 million in the same period in 2022 [139]. - The company has entered into multiple collaboration agreements, including a $100 million agreement with Janssen, which included a $50 million upfront cash payment [129]. - Collaboration revenue increased to $58.98 million for the three months ended March 31, 2023, compared to $18.41 million for the same period in 2022, reflecting a $40.57 million increase attributed to the recognition of deferred revenue from the Janssen contract termination [150]. - Under the Ono Agreement, the company received an upfront payment of $10 million and is eligible for up to $40 million in additional payments based on preclinical milestones [160]. - The company is entitled to receive up to $843.0 million in milestone payments for each candidate under the Ono Agreement, with $10.0 million received in December 2020 and $12.5 million in November 2022 [166]. Research and Development - The company plans to increase research and development expenses to support ongoing clinical trials and the development of its iPSC product platform [141]. - The company has discontinued its FT516, FT596, FT538, and FT536 NK cell programs to focus on more innovative projects [123]. - The company has a research collaboration with the University of Minnesota and Memorial Sloan Kettering Cancer Center to develop engineered NK and T-cell cancer immunotherapies [120]. - Research and development expenses decreased to $65.63 million for the three months ended March 31, 2023, down from $72.14 million in the same period in 2022, a reduction of $6.51 million [151]. Expenses and Cash Flow - General and administrative expenses rose to $21.94 million for the three months ended March 31, 2023, compared to $20.74 million in the same period in 2022, an increase of $1.20 million primarily due to higher patent and legal expenses [151]. - Cash used in operating activities decreased to $28.9 million for the three months ended March 31, 2023, compared to $64.6 million for the same period in 2022, primarily due to a decrease in net loss [155]. - The company incurred $17.1 million in sublicense fees related to the Janssen Agreement, with $15.6 million paid as of March 31, 2023 [159]. - The company reversed the liability associated with the CIRM Award, recording it as other income during the three months ended March 31, 2023, following the discontinuation of the FT516 program [147]. - Other income increased to $9.71 million for the three months ended March 31, 2023, compared to $8.78 million in the same period in 2022, including $4.0 million from the CIRM Award [152]. Capital and Funding - The company may require additional capital for research and development and may seek funds sooner than expected due to various risks, including inflation and global economic conditions [179]. - The company has entered into a sales agreement for an at-the-market offering program, allowing it to sell up to $350.0 million in common stock [176]. - The company received $100 million from the Janssen Agreement, which included a $50 million upfront cash payment and a $50 million equity investment [156]. Market and Economic Factors - Inflationary factors may adversely affect the company's operating results, although no material impact has been observed to date [185]. - The company is exposed to interest rate risk, but a 10% change in market interest rates would not have a material impact on its financial condition [186]. - The company has no material contractual obligations not fully recorded or disclosed in its financial statements [184].